China
Africa
Explore chapters and articles related to this topic
The Non-Hodgkin’s Lymphomas and Plasma Cell Dyscrasias
Published in Harold R. Schumacher, William A. Rock, Sanford A. Stass, Handbook of Hematologic Pathology, 2019
Lynne V. Abruzzo, L. Jeffrey Medeiros
This category in the Revised European-American Classification includes neoplasms previously designated as well or poorly differentiated lymphocytic lymphoma (Rappaport), small lymphocytic lymphoma (Working Formulation), and T-cell prolymphocytic leukemia (French-American-British classification). Some authors believe T-CLL = small cell T:PLL. Others think T-CLL a separate entity!
Pulmonary reactions to chemotherapeutic agents: the ‘chemotherapy lung’
Published in Philippe Camus, Edward C Rosenow, Drug-induced and Iatrogenic Respiratory Disease, 2010
Fabien Maldonado, Andrew H Limper
ATRA has been used with excellent results for the treatment of promyelocytic leukaemia, or acute myeloblastic leukaemia M3 according to the French/American/British classification. The basis for this treatment is the presence of a mutation in the retinoic acid receptor-alpha gene in patients with these disorders, which to a certain extent can be corrected by high doses of ATRA. ATRA thus allows for the maturation of leukaemic cells and can therefore induce disease remission. It is usually used in association with other agents, namely daunorubicin and cytosine arabinoside. ATRA may also prevent the onset of disseminated intravascular coagulation which frequently complicates this type of leukaemia.
CHRONIC LEUKAEMIAS AND MYELODYSPLASTIC DISEASE
Published in James Bishop, Cancer Facts, 1999
Myelodysplastic syndrome (MDS) is an acquired, progressive, clonal disorder of marrow proliferation characterised by dysplasia of the peripheral blood and marrow, cytopenias, and a high risk of transformation to acute leukaemia. The FAB (French, American, British) classification separates de novo MDS into five morphologic subtypes, predominantly on marrow blast percentage (Table 46.3):
Vitamin D-Binding Protein and Acute Myeloid Leukemia: A Genetic Association Analysis in Combination with Vitamin D Levels
Published in Nutrition and Cancer, 2023
Saeedeh Ghazaey Zidanloo, Danial Jahantigh, Nafiseh Amini
AML patients were newly diagnosed and recruited from the cohort of subjects assessed by genetic testing within the molecular pathology research center, Ghaem Hospital, Mashhad University of Medical Sciences, in the northeast provinces of Iran. This case-control study was done on 227 AML patients and 240 age-sex-matched control subjects with no history of cancer. The participants in this follow-up study did not take vitamin D supplements themselves. We counseled and tested 96 children with AML and 131 adult AML subjects in our study. The median age indicates a younger population in AML patients (37.44 ± 4.61 years). Patients were 125 males (55.06%) and 102 females (44.93%). Clinical and demographic information, including age and sex, hemoglobin (Hb), white blood cells (WBC), platelet count at diagnosis, and French-American-British classification (FAB), are summarized in Table 1.
Arsenic trioxide in pediatric cancer – a case series and review of literature
Published in Pediatric Hematology and Oncology, 2021
Michael Abele, Sara-Lena Müller, Sabine Schleicher, Ulrike Hartmann, Michaela Döring, Manon Queudeville, Peter Lang, Rupert Handgretinger, Martin Ebinger
APL forms a subtype of acute myeloid leukemia (AML) which is characterized by M3 morphology in the French-American-British classification.30 APL often exhibits the PML-RARα fusion gene which makes APL susceptible for treatment with all-trans retinoic acid (ATRA) and ATO. Furthermore, Hh is aberrantly activated in APL offering ATO an additional target.31 APL has a share of 4-10% of childhood AML in European and American trials; however in certain ethnic groups such as the Hispanic population higher frequencies of over 20% are found.30,32,33 While ATRA and anthracycline-based chemotherapy were the standard approach for APL for some time, ATO meanwhile has largely replaced conventional chemotherapy in treatment protocols in APL.34 Its synergy with ATRA led to a combination therapy achieving CR rates of over 90% and overall survival (OS) of up to 99%.35–38 ATO is usually applied intravenously with a dose of 0.15 mg/kg per day.
Octamer-binding transcription factor 4 correlates with complex karyotype, FLT3-ITD mutation and poorer risk stratification, and predicts unfavourable prognosis in patients with acute myeloid leukaemia
Published in Hematology, 2018
After enrollment in this study, demographic information of all patients and controls were collected, which included age and sex. For AML patients, FAB classification (according to French–American–British classification systems), cytogenetics (according to An International System for Human Cytogenetic Nomenclature (ISCN 2009)), the mutation status of internal tandem duplications in the FMS-like tyrosine kinase 3 (FLT3-ITD), isolated biallelic CEBPA mutation and nucleophosmin (NPM1) mutation, risk stratification (according to National Comprehensive Cancer Network (NCCN) Clinical Practice Guidelines in Oncology of AML (Version 2.2013)) and white blood cell (WBC) counts were recorded in detail. The median follow-up duration was 17.0 months (1/4–3/4 quartile: 12.0–24.0 months, range 2.0–36.0 months), and the last follow up month was June 2017.